Kerri-Ann  Millar net worth and biography

Kerri-Ann Millar Biography and Net Worth

Kerri-Ann Millar serves as the Chief Financial Officer.  Before joining Cue Biopharma, Ms. Millar served as Corporate Controller for Flexion Therapeutics, Inc., a biopharmaceutical company focused on the development of local therapies for the treatment of patients with osteoarthritis, where she developed the finance function for the newly public company to support the commercialization of its first approved drug. Prior to Flexion Therapeutics, she served as a Finance Specialist for Curis, Inc., a biotechnology company focused on the development of oncology treatments. Prior to Curis, Ms. Millar spent over 10 years in audit and finance functions at several investment banks in the Boston area and four years at PricewaterhouseCoopers. She earned a B.S. in Accounting and Finance from Boston University and is a Certified Public Accountant.

How old is Kerri-Ann Millar?

Ms. Millar is currently 54 years old. There are 7 older executives and no younger executives at Cue Biopharma. The oldest executive at Cue Biopharma is Mr. Colin G. Sandercock J.D., MSE, Senior VP, General Counsel & Secretary, who is 67 years old. Learn More on Kerri-Ann Millar's age.

How do I contact Kerri-Ann Millar?

The corporate mailing address for Ms. Millar and other Cue Biopharma executives is 21 ERIE STREET, CAMBRIDGE MA, 02139. Cue Biopharma can also be reached via phone at (617) 949-2680 and via email at [email protected]. Learn More on Kerri-Ann Millar's contact information.

Has Kerri-Ann Millar been buying or selling shares of Cue Biopharma?

Kerri-Ann Millar has not been actively trading shares of Cue Biopharma within the last three months. Most recently, Kerri-Ann Millar sold 1,251 shares of the business's stock in a transaction on Friday, October 1st. The shares were sold at an average price of $14.21, for a transaction totalling $17,776.71. Learn More on Kerri-Ann Millar's trading history.

Who are Cue Biopharma's active insiders?

Cue Biopharma's insider roster includes Kerri-Ann Millar (CFO), Daniel Passeri (CEO), Kenneth Pienta (Insider), and Anish Suri (Insider). Learn More on Cue Biopharma's active insiders.

Are insiders buying or selling shares of Cue Biopharma?

In the last year, Cue Biopharma insiders bought shares 2 times. They purchased a total of 7,000 shares worth more than $19,620.00. The most recent insider tranaction occured on August, 25th when insider Anish Suri bought 4,000 shares worth more than $11,040.00. Insiders at Cue Biopharma own 10.2% of the company. Learn More about insider trades at Cue Biopharma.

Information on this page was last updated on 8/25/2023.

Kerri-Ann Millar Insider Trading History at Cue Biopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/1/2021Sell1,251$14.21$17,776.71View SEC Filing Icon  
8/29/2018Buy1,000$8.48$8,480.00View SEC Filing Icon  
See Full Table

Kerri-Ann Millar Buying and Selling Activity at Cue Biopharma

This chart shows Kerri-Ann Millar's buying and selling at Cue Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cue Biopharma Company Overview

Cue Biopharma logo
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate with Immuno-STAT targeting the KRAS G12V mutation, as well as cancer antigen MAGE-A4; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; and LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $1.89
Low: $1.85
High: $1.94

50 Day Range

MA: $2.22
Low: $1.77
High: $2.84

2 Week Range

Now: $1.89
Low: $1.70
High: $5.12

Volume

192,115 shs

Average Volume

262,704 shs

Market Capitalization

$85.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04